secwatch.observer — SEC 8-K summary
======================================

Issuer:     HUMANIGEN, INC (—)
CIK:        0001293310
Form:       8-K
Filed at:   2024-01-08T23:59:59+00:00
Accession:  0001214659-24-000421
Event type: other_material
Sentiment:  negative
Materiality: 0.85
Item codes: 1.01, 1.03, 2.03, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Humanigen files Chapter 11, agrees to sell assets to CEO-controlled Taran for up to $20M
--------------------------------------------------------------------------------

- Chapter 11 filed Jan 3 in Delaware; company will operate as debtor-in-possession, pursue court-supervised sale.
- Enters asset purchase agreement with Taran Therapeutics (controlled by CEO Dr. Cameron Durrant) as stalking horse bidder for up to $20M ($2M cash + $18M milestones).
- DIP loan of up to $2M from Taran to fund operations; cash at closing offset by DIP loan balance.
- Common stock holders expected to experience complete or significant loss; trading is highly speculative.
- Sale subject to Bankruptcy Court approval, competing bids, and other conditions; closing expected within ~70 days of petition.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1293310/000121465924000421/0001214659-24-000421-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1293310/000121465924000421/o152468k.htm
  HTML page:      https://secwatch.observer/filing/0001214659-24-000421

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer